BioGaia ABBGLAF 100 EV-to-EBIT is 24.47 as of Jul. 12, 2026, which is 5% below its 10-year median of 25.71. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.38 (Fairly Valued). The stock has 2 warning signs investors should review. Among 689 Drug Manufacturers companies, BioGaia AB ranks worse than 68.36% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BioGaia AB's Enterprise Value for the quarter that ended in Mar. 2026 was $1,099.4 Mil.
BioGaia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB EV-to-EBIT Related Terms
BioGaia AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for BioGaia AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioGaia AB's EV-to-EBIT falls into.
BioGaia AB's current Enterprise Value is $1,119.6 Mil.
BioGaia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a EV-to-EBIT of 24.47 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioGaia AB and its competitors. This is near median its historical median of 25.71. Over the past decade, BioGaia AB's EV-to-EBIT has ranged from 15.19 to 43.55. According to the industry distribution chart, BioGaia AB ranks #471 out of 689 companies in the Drug Manufacturers industry, placing it in the top 68.4%.
Is BioGaia AB's EV-to-EBIT too high?
BioGaia AB's current EV-to-EBIT of 24.47 is near median its 10-year median of 25.71. Over the past 10 years, this metric has ranged from a low of 15.19 to a high of 43.55. The Drug Manufacturers industry median EV-to-EBIT is 15.81. BioGaia AB's value of 24.47 is 54.8% above this industry median. Based on the distribution chart, BioGaia AB ranks #471 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #471 out of 689 companies for EV-to-EBIT. This places BioGaia AB in the lower half of its industry. The industry median EV-to-EBIT is 15.81. BioGaia AB's value of 24.47 is 54.8% above this benchmark. Historically, BioGaia AB's own EV-to-EBIT has ranged from 15.19 to 43.55 over the past decade. While the company's 10-year median is 25.71 vs. the industry median of 15.81, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current EV-to-EBIT of 24.47 is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current EV-to-EBIT is 24.47, which is near median its own 10-year median of 25.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $13.38, compared to a current price of $12.20 — trading 8.8% below its estimated fair value. The current EV-to-EBIT is 24.47, which is near median its 10-year median of 25.71 and 54.8% above the Drug Manufacturers industry median of 15.81. BioGaia AB's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current EV-to-EBIT is 24.47 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 8.8% below its estimated GF Value™ of $13.38.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
EV-to-EBIT: 24.47 (near median its 10-year median of 25.71)
GF Value™: $13.38 vs. price of $12.20 (8.8% below fair value)
Industry Position: 54.8% above the Drug Manufacturers median (#471 of 689)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
